ArticleHaematologica2021

SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.

Magdalena M Gerlach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.